p53 mediated death of cells overexpressing MDM2 by an inhibitor of MDM2 interaction with p53. (scientific article published in March 1999)

The retro-inverso form of a homeobox-derived short peptide is rapidly internalised by cultured neurones: a new basis for an efficient intracellular delivery system.

Q54162483

High prognostic significance of Mdm2/p53 co-overexpression in soft tissue sarcomas of the extremities

Q56566036

Teratogen-induced eye defects mediated by p53-dependent apoptosis

Q71526996

MDM2 gene amplification and transcript levels in human sarcomas: relationship to TP53 gene status

Q72138136

Conserved mechanisms of Ras regulation of evolutionary related transcription factors, Ets1 and Pointed P2

Q73111451

Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain

Q24314763

ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways

Q24321528

Mdm2 promotes the rapid degradation of p53

Q24322597

Interaction between the retinoblastoma protein and the oncoprotein MDM2

Q24323385

Net (ERP/SAP2) one of the Ras-inducible TCFs, has a novel inhibitory domain with resemblance to the helix-loop-helix motif

Q24561871

The ribosomal L5 protein is associated with mdm-2 and mdm-2-p53 complexes

Q24608783

Functional interaction between DP-1 and p53

Q24648034

Regulation of p53 stability by Mdm2

Q27860744

p53, the cellular gatekeeper for growth and division

Q27860990

WAF1, a potential mediator of p53 tumor suppression

Q27861121

DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2

Q28254119

The MDM2 C-terminal region binds to TAFII250 and is required for MDM2 regulation of the cyclin A promoter

Q28255693

Inhibition of cell proliferation by p107, a relative of the retinoblastoma protein

Q28260016

The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53

Q28266637

Stabilization of wild-type p53 by hypoxia-inducible factor 1alpha

Q28267232

Amplification of a gene encoding a p53-associated protein in human sarcomas

Q28270924

The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation

Q28280958

The p53-mdm-2 autoregulatory feedback loop

Q28609811

Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53

Q29614430

Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization

Q29614701

Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53

Q29615851

Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53

Q29617850

Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours

Q29618396

p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding.

Q30428424

Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein.

Q33888123

The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2.

Q33889383

Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein

Q34313966

A functional p53-responsive intronic promoter is contained within the human mdm2 gene

Q34761984

p53 and E2F-1 cooperate to mediate apoptosis

Q35185411

E1A signaling to p53 involves the p19(ARF) tumor suppressor

Q35206764

Synergistic activation of p53 by inhibition of MDM2 expression and DNA damage

Q35671727

E2F1 overexpression in quiescent fibroblasts leads to induction of cellular DNA synthesis and apoptosis.

Q35837977

Deregulated transcription factor E2F-1 expression leads to S-phase entry and p53-mediated apoptosis

Q35885582

Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2

Q36174385

The MDM2 oncoprotein binds specifically to RNA through its RING finger domain

Q36437940

Transcription abnormalities potentiate apoptosis of normal human fibroblasts.

Q36438161

The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth

Q36659029

Molecular characterization of the hdm2-p53 interaction

Q36871109

Immunological evidence for the association of p53 with a heat shock protein, hsc70, in p53-plus-ras-transformed cell lines

Q36919740

The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines

Q37537138

Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: transforming ability and frequent detection in human cancer.

Q38354926

CTS1: a p53-derived chimeric tumor suppressor gene with enhanced in vitro apoptotic properties

Q39796556

mdm-2 inhibits the G1 arrest and apoptosis functions of the p53 tumor suppressor protein

Q40018842

Amplification of MDM2 inhibits MyoD-mediated myogenesis

Q40019821

A transcriptionally active DNA-binding site for human p53 protein complexes

Q40655196

Physical and functional interactions between p53 and cell cycle co-operating transcription factors, E2F1 and DP1.

Q40790222

The p53-MDM2 interaction in a cancer-prone family, and the identification of a novel therapeutic target

Q41024588

Induction of DNA synthesis and apoptosis are separable functions of E2F-1.

Q41099375

E2F1-induced apoptosis requires DNA binding but not transactivation and is inhibited by the retinoblastoma protein through direct interaction

Q41099382

The mdm2 proto-oncogene

Q41100486

Tolerance of high levels of wild-type p53 in transformed epithelial cells dependent on auto-regulation by mdm-2.

Q41115527

Expression of Bcl-xL and loss of p53 can cooperate to overcome a cell cycle checkpoint induced by mitotic spindle damage

Q41158289

P53 gene alterations in human tumors: perspectives for cancer control.

Q41205883

p53; from inductive signal to cellular effect

Q41345451

Mdm-2: "big brother" of p53.

Q41370313

Deregulated expression of E2F-1 induces S-phase entry and leads to apoptosis

Q41415956

P433

issue

P407

language of work or name

English

Q1860

P921

main subject

overexpression

Q61643320

P304

page(s)

1921-1934

P577

publication date

1999-03-01

P1433

published in

Oncogene

Q1568657

P1476

title

p53 mediated death of cells overexpressing MDM2 by an inhibitor of MDM2 interaction with p53.

P478

volume

Reverse relations

cites work (P2860)

Q23912432	Anticancer peptide PNC-27 adopts an HDM-2-binding conformation and kills cancer cells by binding to HDM-2 in their membranes
Q57890248	Bioactive Natural Peptides
Q38052382	Caspase control: protagonists of cancer cell apoptosis
Q58738105	Chemical Instability and Promiscuity of Arylmethylidenepyrazolinone-Based MDMX Inhibitors
Q47717539	Co-operative intra-protein structural response due to protein-protein complexation revealed through thermodynamic quantification: study of MDM2-p53 binding.
Q40842578	Controlled access of p53 to the nucleus regulates its proteasomal degradation by MDM2.
Q35010309	Cytotoxic effect of a non-peptidic small molecular inhibitor of the p53-HDM2 interaction on tumor cells
Q33964769	Defect in the p53-Mdm2 autoregulatory loop resulting from inactivation of TAF(II)250 in cell cycle mutant tsBN462 cells
Q34379259	Differentiation of Hdm2-mediated p53 ubiquitination and Hdm2 autoubiquitination activity by small molecular weight inhibitors
Q42055434	Docking Analysis and Multidimensional Hybrid QSAR Model of 1,4-Benzodiazepine-2,5-Diones as HDM2 Antagonists
Q36558129	Drugs targeting protein-protein interactions
Q35082710	E3 ubiquitin ligases as cancer targets and biomarkers
Q28550874	Energetic Landscape of MDM2-p53 Interactions by Computational Mutagenesis of the MDM2-p53 Interaction
Q29048586	Evaluation of the use of therapeutic peptides for cancer treatment
Q35058579	Inhibiting the p53-MDM2 interaction: an important target for cancer therapy
Q34400571	Inhibition of Siah ubiquitin ligase function.
Q38796979	Inhibition of cell proliferation, migration and invasion by a glioma-targeted fusion protein combining the p53 C terminus and MDM2-binding domain
Q34594105	Intrinsic disorder in scaffold proteins: getting more from less
Q38007557	Intrinsically disordered proteins and novel strategies for drug discovery
Q39989774	Isoquinolin-1-one inhibitors of the MDM2-p53 interaction
Q35081240	Ligand-dependent interaction of the glucocorticoid receptor with p53 enhances their degradation by Hdm2
Q28138926	MDM2--master regulator of the p53 tumor suppressor protein
Q35572466	Mdm2: A regulator of cell growth and death
Q28210052	MdmX is a RING finger ubiquitin ligase capable of synergistically enhancing Mdm2 ubiquitination
Q40200606	Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.
Q34677800	Negative cross-talk between p53 and the glucocorticoid receptor and its role in neuroblastoma cells
Q35011473	Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP.
Q37709228	On the industrial applications of MCRs: molecular diversity in drug discovery and generic drug synthesis
Q23915398	PNC-28, a p53-derived peptide that is cytotoxic to cancer cells, blocks pancreatic cancer cell growth in vivo
Q23918117	Peptides from the amino terminal mdm-2-binding domain of p53, designed from conformational analysis, are selectively cytotoxic to transformed cells
Q40476066	Progesterone inhibition of MDM2 p90 protein in MCF-7 human breast cancer cell line is dependent on p53 levels.
Q46409564	Proneness to UV-induced apoptosis in human fibroblasts defective in transcription coupled repair is associated with the lack of Mdm2 transactivation
Q35397776	Protein-protein interaction modulator drug discovery: past efforts and future opportunities using a rich source of low- and high-throughput screening assays
Q33265016	Protoporphyrin IX interacts with wild-type p53 protein in vitro and induces cell death of human colon cancer cells in a p53-dependent and -independent manner
Q38223668	QTc prolongation induced by targeted biotherapies used in clinical practice and under investigation: a comprehensive review.
Q79733375	Reactivation of the p53 tumor suppressor pathway by a stapled p53 peptide
Q37524156	Recent advances in validating MDM2 as a cancer target.
Q54703151	Sequence-specific 1H, 15N, and 13C assignment of the N-terminal domain of the human oncoprotein MDM2 that binds to p53.
Q27027835	Small molecule compounds targeting the p53 pathway: are we finally making progress?
Q24292513	Sp100 interacts with ETS-1 and stimulates its transcriptional activity
Q35295410	Structural basis for inhibition of the MDM2:p53 interaction by an optimized MDM2-binding peptide selected with mRNA display
Q36020398	Targeting intrinsically disordered proteins in neurodegenerative and protein dysfunction diseases: another illustration of the D(2) concept
Q33655329	Targeting p53 for Novel Anticancer Therapy
Q35903526	Targeting the p53-MDM2 interaction to treat cancer
Q74200562	The contribution of the RING finger domain of MDM2 to cell cycle progression
Q73787111	The contribution of the acidic domain of MDM2 to p53 and MDM2 stability
Q74244104	The initial evaluation of non-peptidic small-molecule HDM2 inhibitors based on p53-HDM2 complex structure
Q23923633	The penetratin sequence in the anticancer PNC-28 peptide causes tumor cell necrosis rather than apoptosis of human pancreatic cancer cells
Q37564522	Therapeutic peptides for cancer therapy. Part I - peptide inhibitors of signal transduction cascades.
Q45878720	Trans-membrane peptide therapy for malignant glioma by use of a peptide derived from the MDM2 binding site of p53.
Q24791038	Transcriptional Targeting in Cancer Gene Therapy
Q45864999	Tumour regression in a ligand inducible manner mediated by a chimeric tumour suppressor derived from p53.
Q30385084	Understanding protein non-folding.
Q28386936	mRNA Display Selection of an Optimized MDM2-Binding Peptide That Potently Inhibits MDM2-p53 Interaction
Q37982458	p53-Mdm2 inhibitors: patent review (2009 - 2010).

P356	DOI	10.1038/SJ.ONC.1202528
P2888	exact match	https://scigraph.springernature.com/pub.10.1038/sj.onc.1202528
P698	PubMed publication ID	10208414
P5875	ResearchGate publication ID	13090688